Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 84Observational 4Expanded_access 1

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Dermatologic 1

Conditions

Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × cemiplimab × Clear all
NCT05363319 2026-05-13

CEMI-LUNG

Regeneron Pharmaceuticals

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Regeneron Pharmaceuticals

Active not recruiting
1,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT03836105 2025-10-15

CASE

Regeneron Pharmaceuticals

Completed
287 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT05302297 2022-12-13

TOSCA

Sanofi

Completed
305 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡